Guangdong Hengrui Pharmaceutical Co., Ltd
Clinical trials sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd, explained in plain language.
A subsidiary of Jiangsu Hengrui Pharmaceuticals, involved in the development and manufacturing of pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot for eczema shows promise in early trial Results expected Sep 2026 (estimated)
- New inhaled powder for COPD heads into first human tests Results expected Sep 2026 (estimated)
- New inhaler hope for COPD patients in early trial Results expected Oct 2026 (estimated)
- New injection could tame seasonal allergy symptoms for those failed by standard treatments Results expected Dec 2026 (estimated)
- Can an experimental injection clear stubborn psoriasis? a new trial aims to find out. Results expected Dec 2026 (estimated)
-
New asthma drug aims to slash severe attacks in eosinophilic patients
Disease control OngoingThis study tests a new medicine called SHR-1703 to see if it can reduce asthma attacks in people with eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. About 400 participants aged 12 and older who already use daily inhaled steroids and othe…
Phase 3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug shows promise for ulcerative colitis in early trial
Disease control OngoingThis study tests a new medicine called SHR-1139 in 21 adults with moderate-to-severe ulcerative colitis, a condition that causes inflammation in the colon. The treatment has two parts: 12 weeks of induction therapy followed by 48 weeks of maintenance therapy. The main goal is to …
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot aims to ease arthritis pain in 30-Patient trial
Disease control OngoingThis study tests an experimental injection called SHR-3045 in 30 adults with moderate to severe rheumatoid arthritis who did not get enough relief from other treatments. The goal is to see if it safely reduces joint pain and swelling. Participants are randomly assigned to receive…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for advanced tumors? first human trial of SHR-4712 begins
Disease control OngoingThis early-stage study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Participants receive the drug until their disease gets worse or …
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New shot shows promise for severe eczema sufferers
Symptom relief OngoingThis study tests an experimental drug called SHR-1819 in 201 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it can significantly improve skin symptoms and reduce itching. Participants receive either the drug or a placebo, and researchers track sk…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC